Dr. Tiacci on Standard of Care in Hairy Cell Leukemia Treatment

Video

Enrico Tiacci, MD, discusses the current treatment options for patients with hairy cell leukemia. Currently, the standard of care for these patients are purine nucleoside analogs, including pentostatin and cladribine.

Enrico Tiacci, MD, associate professor of hematology, University and Hospital of Perugia, Italy, discusses the current treatment options for patients with hairy cell leukemia in an interview during the 2019 Hairy Cell Leukemia Foundation Annual Conference.

Currently, the standard of care for these patients are purine nucleoside analogs, including pentostatin and cladribine. Both of these agents elicit high complete response rates in the order of 80% to 90%. Additionally, patients with hairy cell leukemia treated with either of these agents have experienced prolonged median responses.

<<< View more from the 2019 Hairy Cell Leukemia Foundation Annual Conference

Related Videos
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center